AKY-1189 is a novel Nectin-4 targeted radiopharmaceutical product candidate demonstrating substantial tumor uptake across several solid tumor types and is progressing in human development as a therapeutic agent AKY-1189 was engineered to deliver actinium-225 directly to tumors while...
AKTIS ONCOLOGY ANNOUNCES PRESENTATION OF THE FIRST CLINICAL DATA SUPPORTING BROAD DEVELOPMENT OF A FIRST IN CLASS NECTIN-4 TARGETING RADIOPHARMACEUTICAL AKY-1189 AT 2024 EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments